<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126277</url>
  </required_header>
  <id_info>
    <org_study_id>CVAY736K12301</org_study_id>
    <secondary_id>2020-005830-14</secondary_id>
    <nct_id>NCT05126277</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis</brief_title>
  <acronym>SIRIUS-LN</acronym>
  <official_title>A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab&#xD;
      given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with&#xD;
      SoC, in adult participants with active LN&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will evaluate the efficacy, safety, and tolerability of subcutaneous (s.c.)&#xD;
      ianalumab given every 4 weeks (q4w) or ianalumab given every 12 weeks (q12w) compared to&#xD;
      placebo, in combination with SoC, in adult participants with active LN (ISN/RPS class III, IV&#xD;
      active glomerulonephritis with or without co-existing class V features, or pure class V&#xD;
      membranous). using the 2003 International Society for Nephrology (ISN)/Renal Pathology&#xD;
      Society (RPS) criteria).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 3, 2022</start_date>
  <completion_date type="Anticipated">September 3, 2029</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a pivotal double-blind, randomized, placebo-controlled, multi-center three-arm study, evaluating at Week 72 efficacy and safety of ianalumab administered s.c. every 4 weeks or ianalumab administered s.c. every 12 weeks versus placebo, administered s.c. every 4 weeks, in adult participants with active LN receiving SoC. In addition, long-term efficacy, safety and tolerability will be collected up to Week 144.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and percentage of participants achieving complete renal response (CRR)</measure>
    <time_frame>week 72</time_frame>
    <description>The primary objective is to demonstrate superiority of ianalumab compared to placebo, in achieving stable CRR (defined as estimated glomerular filtration rate (eGFR) ≥90 ml/min/1.73 m2 or no less than 85% of baseline, AND, 24-hour UPCR &lt;0.5) at Week 72 in active lupus nephritis (ISN/RPS class III, IV active glomerulonephritis with or without co-existing class V features, or pure class V membranous) participants on background SoC therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of Urine protein/creatinine ratio (UPCR) &lt;0.5 or ≥50% reduction from baseline</measure>
    <time_frame>Week 72</time_frame>
    <description>To demonstrate superiority of ianalumab, compared to placebo, in time to first occurrence of UPCR &lt; (urine protein-to-creatinine ratio) (UPCR) 0.5 or ≥50% reduction from baseline up to Week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving stable Overall Renal Response (ORR), defined as achievement as either CRR or Partial Renal Response (PRR)</measure>
    <time_frame>Week 52</time_frame>
    <description>To demonstrate superiority of ianalumab, compared to placebo, in achieving stable ORR at Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of stable Complete Renal Response (CRR) and average daily corticosteroid dose ≤5mg/day</measure>
    <time_frame>Week 72</time_frame>
    <description>To demonstrate superiority of ianalumab, compared to placebo, in achieving stable CRR at Week 72 and average daily corticosteroid dose ≤5mg/day between Week 24 and Week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of renal or extra-renal flares</measure>
    <time_frame>Week 72</time_frame>
    <description>To demonstrate superiority of ianalumab, compared to placebo, in reducing renal or extra-renal flares from Week 24 through Week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in British Isles Lupus Activity Group (BILAG) score</measure>
    <time_frame>Week 72</time_frame>
    <description>To demonstrate superiority of ianalumab, compared to placebo in BILAG-2004 at Week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score</measure>
    <time_frame>Week 72</time_frame>
    <description>To demonstrate superiority of ianalumab, compared to placebo, in FACIT-Fatigue at Week 72</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Week 72</time_frame>
    <description>Adverse Events (AEs) are any untoward sign or symptom that occurs during the study treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pulse rate of participants per treatment group</measure>
    <time_frame>Week 72</time_frame>
    <description>Beats per minute (BPM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Pressure of participants</measure>
    <time_frame>Week 72</time_frame>
    <description>Blood pressure is measured using two numbers:&#xD;
The first number, called systolic blood pressure, measures the pressure in your arteries when your heart beats.&#xD;
The second number, called diastolic blood pressure, measures the pressure in your arteries when your heart rests between beats.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ianalumab concentration in serum</measure>
    <time_frame>Week 72</time_frame>
    <description>To characterize the pharmacokinetics (PK) of ianalumab mean, median, minimum and maximum concentrations will be provided</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and titer of anti-ianalumab antibodies in serum (ADA assay) over time</measure>
    <time_frame>Week 72</time_frame>
    <description>To evaluate immunogenicity of ianalumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Arm 1 - ianalumab s.c. q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ianalumab s.c. q4w in addition to standard of care (SoC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - ianalumab s.c. q12w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ianalumab s.c. q12w in addition to SoC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 - placebo s.c. q4w</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo s.c. q4w in addition to SoC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ianalumab s.c. q4w</intervention_name>
    <description>ianalumab s.c. q4w in addition to SoC</description>
    <arm_group_label>Arm 1 - ianalumab s.c. q4w</arm_group_label>
    <other_name>VAY736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ianalumab s.c. q12w</intervention_name>
    <description>ianalumab s.c. q12w in addition to SoC</description>
    <arm_group_label>Arm 2 - ianalumab s.c. q12w</arm_group_label>
    <other_name>VAY736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo s.c.</intervention_name>
    <description>placebo s.c. q4w in addition to SoC</description>
    <arm_group_label>Arm 3 - placebo s.c. q4w</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants eligible for inclusion in this study must meet all of the following criteria:&#xD;
&#xD;
        Adult male and female participants aged 18 years or older at the time of baseline&#xD;
&#xD;
        Weigh at least 35 kg at screening&#xD;
&#xD;
        Have a confirmed clinical diagnosis of SLE according to European League Against&#xD;
        Rheumatism/American College of Rheumatology (EULAR/ACR) Systemic lupus erythematosus (SLE)&#xD;
        classification criteria&#xD;
&#xD;
        Have a positive anti-nuclear antibody (ANA) test result; ANA titer ≥1:80 at screening visit&#xD;
        based on central laboratory result&#xD;
&#xD;
        Active LN at screening, as defined by meeting the 3 following criteria:&#xD;
&#xD;
          -  Biopsy within 6 months prior to screening period indicating ISN/RPS class III or IV&#xD;
             active glomerulonephritis with or without co-existing class V features, or pure class&#xD;
             V membranous LN. If no biopsy was performed within 6 months prior to screening period,&#xD;
             a biopsy will need to be performed during the screening period after having met all&#xD;
             other inclusion/exclusion criteria.&#xD;
&#xD;
          -  UPCR ≥1.0 on 24h urine collection at Screening&#xD;
&#xD;
          -  eGFR ≥25mL/min/1.73 m2&#xD;
&#xD;
        Participants must be currently on, or willing to initiate SoC induction therapy for LN&#xD;
        according to the institutional practices using MPA&#xD;
&#xD;
        Receipt of at least one dose of pulse methylprednisolone i.v. (500-1000 mg) or equivalent&#xD;
        for treatment of current episode of active LN during past 60 days prior screening&#xD;
&#xD;
        Able to communicate well with the Investigator to understand and comply with the&#xD;
        requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants meeting any of the following criteria are not eligible for inclusion in this&#xD;
        study.&#xD;
&#xD;
        Severe renal impairment as defined by i.) Stage 4 Chronic Kidney Disease (CKD), or ii.)&#xD;
        presence of oliguria (defined as a documented urine volume &lt;400 mL/24 hrs), or iii.)&#xD;
        End-Stage Renal Disease (ESRD) requiring dialysis or transplantation&#xD;
&#xD;
        Sclerosis in &gt;50% of glomeruli on renal biopsy&#xD;
&#xD;
        Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or&#xD;
        until the expected pharmacodynamic effect has returned to baseline&#xD;
&#xD;
        Prior use of any B cell depleting therapy within 36 weeks prior to randomization or as long&#xD;
        as B cell count &lt;50 cells/μL&#xD;
&#xD;
        Prior treatment with any of the following within 12 weeks prior to randomization&#xD;
&#xD;
          -  belimumab, abatacept, TNF-α mAb, immunoglobulins (i.v./s.c.) plasmapheresis&#xD;
&#xD;
          -  any other immuno-suppressants (i.v. or oral cyclophosphamide, calcineurin inhibitors,&#xD;
             JAK inhibitors or other kinase inhibitors)&#xD;
&#xD;
          -  thalidomide treatment and/or one of the following DMARDs: methotrexate or an imidazole&#xD;
             derivative (e.g., azathioprine, mizoribine)&#xD;
&#xD;
        Receipt of more than 3000 mg i.v. pulse methylprednisolone (cumulative dose) within 12&#xD;
        weeks prior to Baseline&#xD;
&#xD;
        History of major organ transplant or hematopoietic stem cell/bone marrow transplant or are&#xD;
        due to receive transplantation&#xD;
&#xD;
        Any one of the following laboratory values at screening:&#xD;
&#xD;
          -  Hemoglobin levels &lt;8.0 g/dL&#xD;
&#xD;
          -  Platelet count &lt;75 x 1000/µL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1.0 x 1000/µL&#xD;
&#xD;
        Active viral, bacterial or other infections requiring systemic treatment at the time of&#xD;
        screening, or history of recurrent clinically significant infection or of bacterial&#xD;
        infections with encapsulated organisms&#xD;
&#xD;
        History of known intolerance/hypersensitivity to MPA, oral corticosteroids, or any&#xD;
        component of the study drug(s) or its excipients&#xD;
&#xD;
        Receipt of live/attenuated vaccine within a 4-week period prior to randomization&#xD;
&#xD;
        History of primary or secondary immunodeficiency, including a positive HIV test result&#xD;
&#xD;
        History of malignancy of any organ system (other than localized basal cell carcinoma or&#xD;
        squamous cell carcinoma of the skin or or in-situ cervical cancer), treated or untreated,&#xD;
        within the past 5 years, regardless of whether there is evidence of local recurrence or&#xD;
        metastases&#xD;
&#xD;
        Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes),&#xD;
        psychiatric or additional physical condition that the Investigator feels may jeopardize the&#xD;
        patient in case of participation in this study&#xD;
&#xD;
        Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). Positive serology for&#xD;
        hepatitis B surface antigen (HBsAg) excludes the participant.&#xD;
&#xD;
        Evidence of active tuberculosis (TB) infection (after anti-TB treatment, participants with&#xD;
        history of TB may become eligible according to national guidelines).&#xD;
&#xD;
        Pregnant or nursing (lactating) women&#xD;
&#xD;
        Women of child-bearing potential, defined as all women physiologically capable of becoming&#xD;
        pregnant, unless they are using highly effective methods of contraception during dosing and&#xD;
        for 6 months after stopping of investigational medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>Kidney inflammation</keyword>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>anti-BAFF-receptor</keyword>
  <keyword>B-cell depletion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

